Results 81 to 90 of about 536 (130)

EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1 [PDF]

AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1. METHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016. We followed them
OHSHIMA, Shigetoshi, Miura, Masato, KURAMITSU, Tomoyuki, FUJISHIMA, Yuukou, WATANABE, Daisuke, NAKANE, Kunio, Goto, Mitsuo, AJIMINE, Takuma, YAGISAWA, Hitoshi, NAKAJIMA, Kou, GOTO, Takashi, IIJIMA, Katsunori, HOSHINO, Takao, Inomata, Masaaki, KOMATSU, Masafumi, FUNAOKA, Masato, Segawa, Daisuke   +16 more
core   +2 more sources

Additional file 1: of Modulation of chimeric antigen receptor surface expression by a small molecule switch

, 2019
Figure S1. Proliferation of T-cells in the presence of increasing concentrations of Asunaprevir. The total number of cells at different days cultured in presence of 100 nM, 500 nM or 1000 nM relative to 0 nM ASN is presented. (A) Donor 1.
Alexandre Juillerat (152077), Brian Busser (6913508), Aymeric Duclert (6021), Laurent Poirot (6913514), Philippe Duchateau (22729), Diane Tkach (6913502), Stéphane Depil (413777), Julien Valton (484265), Sonal Temburni (6913511)   +8 more
core   +1 more source

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives

The Scientific World Journal, 2013
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (
Hee Bok Chae, Seon Mee Park, Sei Jin Youn   +2 more
doaj   +1 more source

Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C [PDF]

, 2016
Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures.
Konno, Jun, Izumi, Takaaki, Terashita, Katsumi, Natsuizaka, Mitsuteru, Kimura, Megumi, Tateyama, Miki, Yamamoto, Yoshiya, Shinada, Keisuke, Sakamoto, Naoya, Sato, Fumiyuki, Morikawa, Kenichi, Sho, Takuya, Umemura, Machiko, Nagasaka, Atsushi, Tsukuda, Yoko, Nakai, Masato, Furuya, Ken, Kudo, Mineo, Kobayashi, Tomoe, Suda, Goki, Ogawa, Koji, Tsunematsu, Seiji, Yamasaki, Kazushi, Horimoto, Hiromasa   +23 more
core   +1 more source

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

PLoS ONE, 2017
The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients. However, the risk in patients treated with interferon-free direct-acting antivirals (DAAs) is unknown. We
Yuko Nagaoki, Michio Imamura, Hiroshi Aikata, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Masahiro Hatooka, Reona Morio, Kei Morio, Hiromi Kan, Hatsue Fujino, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Yoshiiku Kawakami, C Nelson Hayes, Daiki Miki, Hidenori Ochi, Kazuaki Chayama   +23 more
doaj   +1 more source

Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China

, 2018
Aim: To evaluate the cost–effectiveness of the novel all-oral direct-acting antiviral regimen daclatasvir + asunaprevir (DUAL), versus interferon-based regimens for the treatment of chronic hepatitis C virus genotype 1b infection.
Peter Feng Wang, Gail D Wygant, Jason Gordon, Thomas Ward, Jing Yan, Wen Chen, Mai Ping Tan   +6 more
core   +1 more source

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents

Kaohsiung Journal of Medical Sciences, 2017
Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive.
Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Jeng-Fu Yang, Ching-I. Huang, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang   +12 more
doaj   +1 more source

Incremental cost effectiveness analysis: DCV/ASV versus PR and PIs considering two prices.

, 2015
PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, QALY: Quality Adjusted Life Years, ICER: Incremental cost effectiveness ratio, 1 $US = 620 CLP.Incremental cost effectiveness analysis: DCV/ASV versus PR ...
Alejandro Soza (823197), Manuel A. Espinoza (823195), Constanza L. Vargas (823194), Andrés Giglio (823196)   +3 more
core   +1 more source

Expected Hepatitis C complications in patients treated with DCV/ASV versus PR.

, 2015
HCV: Hepatitis C Virus, PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, F4: cirrhosis, DC: Decompensated cirrhosis, HCC: hepatocellular carcinoma, HT: liver transplant, BCI: Bayesian credibility interval.
Alejandro Soza (823197), Manuel A. Espinoza (823195), Constanza L. Vargas (823194), Andrés Giglio (823196)   +3 more
core   +1 more source

Probabilistic sensitivity analysis considering four DCV/ASV prices.

, 2015
PR: Peginterferon plus Ribavirin, PIs: Protease Inhibitors, DCV/ASV: Daclatasvir plus Asunaprevir, QALY: Quality Adjusted Life Years, ICER: Incremental cost effectiveness ratio, 1 $US = 620 CLPaMontecarlo simulation (5,000 iterations)bConsidering a ...
Alejandro Soza (823197), Manuel A. Espinoza (823195), Constanza L. Vargas (823194), Andrés Giglio (823196)   +3 more
core   +1 more source